Earnings call transcript: Corcept beats Q3 2026 estimates, shares slip after hours

Corcept Therapeutics reported Q3 2026 revenue of $340.5 million, up 64% year over year, and adjusted EPS of $1.01 versus $0.79 expected; Lifyorli revenue reached $91.4 million, up 92% sequentially. Net income was $126.8 million, and the company repurchased $44 million of stock, but it reiterated 2026 revenue guidance of $1.1 billion–$1.2 billion. Shares rose 1.83% in regular trading and fell 2.36% after hours; relacorilant’s FDA decision is scheduled for Dec. 17, 2026.

Analysis

The market’s key question is not whether demand is strong, but how much of the current trajectory converts into durable, forecastable earnings. Lifyorli’s early growth is encouraging, yet launch cohorts and increasing repeat prescribing do not establish mature treatment duration or eventual share; management’s billion-dollar ambition remains a company claim, not a validated base case. The mention of Genmab’s Rina-S is a competitive watch item, but the available detail does not support concluding that it displaces Lifyorli. New therapies could also expand treatment options and create combination opportunities, though those require clinical and commercial proof.

CORT still has meaningful exposure to Korlym and its authorized generic. Wider screening could enlarge the diagnosed pool, but adoption depends on physicians changing practice, so the revenue effect is more likely to accrue over quarters and years than immediately. Relacorilant’s December 17 PDUFA is the near-term binary catalyst: approval could support treatment-naive patient growth, while a delay or adverse decision would leave the current franchise carrying more of the growth burden. Approval would not automatically establish launch uptake or incremental rather than substitutional sales. Treat broader oncology, MASH and ALS claims as pipeline optionality until data mature. After a substantial share-price run, execution and regulatory risk leave less room for disappointment; unchanged guidance merits monitoring, not an assumption that management is signaling weakness.

Key Decisions for Investors

• Avoid chasing CORT before the December 17 PDUFA. Keep any existing exposure sized for a binary outcome; consider a defined-risk put spread or partial trim only if option pricing is reasonable. A delay or negative FDA decision falsifies the near-term expansion case; approval alone is not sufficient confirmation without launch and guidance follow-through.
• For a new long, wait for the FDA decision and the next commercial update. Add only if approval is followed by evidence that relacorilant is reaching treatment-naive patients without material Korlym erosion, and Lifyorli repeat use and earlier-line adoption continue to broaden.
• Track Lifyorli patient starts, treatment duration, repeat prescribing and regimen mix, alongside Korlym/authorized-generic pricing and volume. Weakening repeat use or a material slowdown in the core franchise would challenge the thesis even if headline quarterly sales remain strong.
• Keep GMAB on the competitive watch list, not as a direct hedge or trade on this information alone. Verify Rina-S trial data, timing and positioning against Lifyorli before changing relative exposure; combination potential is a hypothesis, not established economics.